So much to say on #ESSENCE Placebo response = sampling variability, see cghjournal.org/article/S1542-… Also, improvements in steatosis at least are mediated through weight loss, see jhep-reports.eu/article/S2589-… Elliot Tapper

En route to EASLnews #ILC2025 to hear the latest offerings in hepatology research. Looking forward to meeting up with friends and colleagues for the next 4 days! Debbie Shawcross Jeffrey V. Lazarus Oliver Tavabie FattyLiverAlliance Tom Marjot Wenhao Li Kohilan Gananandan John Dillon

The first MASH Cities study is out in Hepatology Communications doi.org/10.1097/HC9.00… And the second submitted. Follow us on LinkedIn: linkedin.com/company/mashci… #LiverTwitter #EASLCongress

fg.bmj.com/content/early/… BASL education feed EASLnews LiverAHPs #livertwitter

It was an absolute delight to contribute to this high-impact work with Tom Marjot Matthew Armstrong 💙 in which we review all things #MASLD and #Muscle related! If you're looking for holiday weekend reading, look no further: journals.lww.com/hepcomm/pages/… Hepatology Communications Elliot Tapper

📢Great to write this Hepatology Communications review with Matthew Armstrong 💙 & Jonathan G. Stine, MD MSc, FACP 💪We've covered everything you need to know about #Muscle & #MASLD - Insulin resistance - Sarcopenia - Myosteatosis - Impact of weight loss drugs - Benefits of exercise 🔗shorturl.at/aFO1Q

It was a real pleasure to interview Scott Isaacs and Paul Brennan regarding their recent paper on 'Anti-diabetic medications in MASLD' in Frontline Gastro - listen to two true experts discuss this interesting area on the link below fgbmj.podbean.com/e/role-of-anti…

Please enjoy our #FGPodcast on diabetes medications for #MASLD with Paul Brennan and Oliver Tavabie for Frontline Gastro. fgbmj.podbean.com/e/role-of-anti…

✨ 🆕 #FGPodcast 🚨 alert ➡️ 👂Check out Oliver Tavabie interview Scott Isaacs ➕ Paul Brennan on the "Role of anti-diabetic medications in the management of MASLD" 🔗 Link to 📻 #FGPodcast ⬇️ and relevant article 📰 bit.ly/3FALQDe ▶️ Apple: apple.co/3SXaUr5 ▶️

Metabolic dysfunction-associated steatohepatitis (MASH) drives rising morbidity and mortality, yet remains underdiagnosed. A new Health Policy paper by Jeffrey V. Lazarus and colleagues calls for community-based diagnostics: shorturl.at/a0COQ #LiverTwitter #SLDthinktank

We're at a critical point of needing to scale case-identification of those at risk of significant liver disease. Thanks to The Guardian for highlighting our study now available in the The Lancet Reg Health-Europe theguardian.com/society/2025/j… thelancet.com/journals/lanep… Jeffrey V. Lazarus Mazen Noureddin, MD, MHSc

The Global Think-tank on Steatotic Liver Disease is proud to announce two groundbreaking publications: The People-First Liver Charter, in Nature Medicine nature.com/articles/s4159… 2. A call for doubling the MASH diagnostic rate: thelancet.com/journals/lanep… #SLDthinktank #LiverTwitter

Delighted to be able to contribute to these two really important pieces. And thanks again to The Guardian for highlighting our work on modelling the doubling of MASH diagnoses and what it will take.

Listen to myself and Kohilan Gananandan talk to Stuart Mcpherson Lynsey C and Gio McGinty about the updated bundle in Frontline Gastro and means to implement it ▶️ Apple: podcasts.apple.com/us/podcast/dec… ▶️ Spotify: open.spotify.com/episode/0BF5wP… ▶️ Web: fgbmj.podbean.com/e/decompensate… BSG Trainees BASL education feed

🤩 Very excited to announce our new impact factor 😊. FG going onwards and upwards 🚀 . Thanks to all our brilliant editors, reviewers and all of you who have submitted your fantastic work to the journal 🙏 👏. Remember we are a home for everyone, do continue to submit your work

The ⁦Gut Journal⁩ ⁦Frontline Gastro⁩ session at #BSGlive25 was fantastic - credit to all the speakers. FG has come a long way the past year - feel lucky to work with all the team but especially our EiC ⁦Phil Smith⁩ and co dep ed ⁦Aditi Kumar⁩

📝 New blog alert from Frontline Gastro! GLP-1s, tirzepatide & MASLD: A new frontier for gastroenterologists How should we respond to the rise of weight-loss pharmacotherapy in liver disease care? 📚 This blog explores: – Where GLP-1s fit in MASLD management – The shifting

A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis Jeffrey V. Lazarus The Lancet Gene Im Naim Alkhouri pubmed.ncbi.nlm.nih.gov/40672054/

Recent expert commentary and the flagship event of the Global Think-Tank signal a long-overdue policy reckoning for chronic liver disease sldthinktank.com/policy_and_ins… #LiverTwitter #SLDthinktank AASLD Int. Diabetes Fed. EASL Advocacy NCD Alliance World Obesity FattyLiverAlliance

Dr Mou Sengupta:,transplant hepatologist, mother, innovator. She developed a truly inspiring integrative care program for alcohol-related liver disease at Cleveland clinic. She was thriving. it is an injustice that she has passed. slonecares.com/obituaries/dr-…